#Tech Stocks Added: $SYNC, $AIF.TO, $IMI, $ITRN, $LIOX, $MXPT, $PERI, $TISA, $UNXL, $TTD, Tel Aviv:ALMO.TA and CSE:NUR

#Tech Stocks Added: $SYNC, $AIF.TO, $IMI, $ITRN, $LIOX, $MXPT, $PERI, $TISA, $UNXL, $TTD, Tel Aviv:ALMO.TA and CSE:NUR

Point Roberts, WA, Delta BC – September 23, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories within technology, mining, beverage and cannabis.

Companies added in the tech sector include cloud computing, software, semiconductor, internet advertising, and wireless stocks that trade on the Tel Aviv, Canadian and NASDAQ exchanges.

Also within the tech sector is a new listing in one of our fastest growing sub-sectors: GPS and Tracking Devices - Ituran Location & Control Ltd. (NASDAQGS: ITRN).  Ituran provides location-based services, consisting predominantly of stolen vehicle recovery and tracking services, as well as wireless communications products used in connection with its location-based services and various other applications. Ituran offers mobile asset location, Stolen Vehicle Recovery, management & control services for vehicles, cargo and personal security.

New Mining Companies all trade on the TSX Venture Exchange and the latest addition to our cannabis list is Vitality Biopharma, Inc. (OTC:VBIO) which is looking to cannabinoids for the treatment of serious neurological and inflammatory disorders. 

Added to our Food and Beverage Stocks List is Craft Beer Company, Evans Brewing Company Inc. (OTC:ALES) which develops and distributes premium award-winning craft brands and has future plans that include the opening of the company's first restaurant/taproom, The Public House by Evans Brewing Company.

Read full release: http://www.investorideas.com/news/2016/technology/09231Stocks.asp

Technology Companies Added:

Synacor, Inc. (NasdaqGM:SYNC), Altus Group Ltd. (TSX:AIF.TO), Algomizer, Ltd. (Tel Aviv: ALMO.TA),  Intermolecular, Inc. (NasdaqGS: IMI),  Ituran Location & Control Ltd. (NASDAQGS: ITRN), Lionbridge Technologies Inc. (NasdaqGS: LIOX), MaxPoint Interactive, Inc. (NasdaqGM:MXPT), NuRAN Wireless Inc. (CSE: NUR), Perion Network Ltd. (NasdaqGS:PERI), Top Image Systems Ltd. (NasdaqCM:TISA), UniPixel, Inc. (NasdaqCM: UNXL) and Trade Desk, Inc., The (NasdaqGM:TTD)    

Mining Companies Added:

Ashanti Gold Corp. (TSX:AGZ.V), Sienna Resources Inc (TSX:SIE.V; OTC: SNNAF),   Inovent Capital Inc. (TSX: IVQ-P.V) and Alset Energy Corp. (TSX:ION.V)

Cannabis/Biotech Stock Added:

Vitality Biopharma, Inc. (OTC:VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.

Beverage Stock Added:

Evans Brewing Company Inc. (OTC:ALES) develops and distributes premium craft brands including a superior line of lagers and ales that have been honored with over 20 international awards. Operating the oldest brewery in Orange County, California, Evans Brewing supplies restaurants, retailers and beer drinkers across several states. Future plans include the opening of the company's first restaurant/taproom, The Public House by Evans Brewing Company, broader product distribution, and potentially an expansion of the beer brands currently under management.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Cyprium Mining (TSX: $CUG.V) Debenture Holders Approve Extension Of Maturity Date To February 28th, 2019

Cyprium Mining (TSX: $CUG.V) Debenture Holders Approve Extension Of Maturity Date To February 28th, 2019

All other matters presented at debenture holders meeting also approved

Montreal - September 22, 2016 (Investorideas.com Newswire) Cyprium Mining Corporation ("Cyprium" or the "Company") (TSX-V: CUG and CUG.DB) is pleased to announce that at a special meeting of debenture holders held on September 21 st, 2016 (the "Meeting") the holders of $750,000 in principal amount of unsecured debentures bearing interest at 12% per annum (the "Debentures") overwhelmingly approved all matters presented, including the extension of the maturity date from February 28 th, 2017 to February 28 th, 2019. The Corporation had issued the Debentures under a debenture indenture dated February 28, 2014 (the "Indenture"). The Debentures were entitled to be voted at the Meeting on the basis of one vote for each one dollar of principal amount.

The matters approved at the Meeting are to: (i) authorize CST Trust Company, as debenture trustee, to grant an extension of time for payment of principal on the Debentures from February 28th, 2017 to February 28th, 2019 , (ii) amend the Indenture to allow past due and future interest to be payable through the issuance of common shares in the capital of the Corporation (the "Common Shares"), (iii) amend the Indenture to allow for conversion of the principal amount and any accrued and unpaid interest of the Debentures into Common Shares, the option of the holder, at a price per Common Share equal to $0.10 before February 28th, 2017 and $0.15 thereafter; (iv) approve the delisting of the Debentures from the TSX Venture Exchange; and (v) waive any past defaults, and direct the debenture trustee to waive any past defaults, on the part of the Corporation in complying with any and all provisions of the Indenture.

The Corporation is also pleased to announce that it has extended the maturity of US $1,026,000 of 12.5% bonds from March 15 th, 2018 to January 1 st, 2019 (the "Bonds"). The Bonds were issued as part of the bond financing announced by Cyprium in March 2015 . As part of the amendment of the Bonds, the Corporation was granted the option to pay all interests in common shares of the Corporation.

Alain Lambert , Chairman and CEO of Cyprium commented: "I'm glad to report that 96.8% of the principal amount of debentures voted at the meeting were in favour of all matters presented. This sends a clear message of support for the company's business plan. Our objective remains to finalize in the next two weeks further extensions of the maturity date of various loans so that at least 90% of the company's loans will mature in 2019. Achieving this objective will pave the way for greater access to the equity market as well as possible corporate transactions to ensure the development of the Potosi mine and the La Chinche exploration property."

Read this release in full at http://www.investorideas.com/CO/CUG/news/2016/09221MaturityDate.asp

About Cyprium Mining Corporation

For further information, please contact:

Alain Lambert, Chairman and C.E.O.
ir@cypriummining.com

Ron Keenan, C.O.O.
rkeenan@cypriummining.com
Phone + 1 514 915 3836

www.cypriummining.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" (within the meaning of applicable Canadian securities laws) and "forward -looking statements" (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as "anticipate", "believe", "expect", "plan", "intend", "potential", "estimate", "propose", "project", "outlook", "foresee" or similar words suggesting future outcomes or statements regarding an outlook. Such statements include, among others, those concerning the Company's anticipated plans for developments of the Company and its mining projects".

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management's expectations regarding future growth, plans for and completion of projects by Company's third party relationships, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, operational risks in the completion of Company's anticipated projects, delays or changes in plans with respect to the development of Company's anticipated projects by Company's third party relationships, risks affecting the ability to develop projects, risks inherent in operating in foreign jurisdictions, the ability to attract key personnel, and the inability to raise additional capital. No assurances can be given that the efforts by the Company will be successful. Additional assumptions and risks are set out in detail in the Company's MD&A, available on SEDAR at www.sedar.com.

Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company's securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law. Investors should note that the Potosi silver mine and La Chinche property have no established mineral resources or mineral reserves as defined by NI 43-101. Although Cyprium Mining has made a production decision regarding the Potosi silver mine based on historical production records and results from recent sampling, a feasibility study of its projects has not been completed and there is no certainty that the proposed operations will be economically or technically viable.

SOURCE Cyprium Mining Corporation

Visit this Company: www.cypriummining.com    

More info on CUG.V at Investorideas.com:http://www.investorideas.com/CO/CUG/

Sign up for the free investor news and stock alerts:

http://www.investorideas.com/Resources/Newsletter.asp

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Cyprium Mining Corporation: six month news, PR and social media mining program for 9700 starting August 12, 2016

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Gopher Protocol (OTCQB: $GOPH) Introduces Its Guardian Sphere

Gopher Protocol (OTCQB: $GOPH) Introduces Its Guardian Sphere

SAN DIEGO, CA - September 21, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB:GOPH) ("Gopher" and the "Company"), a development-stage company which specializes in the development of real-time, heuristic-based mobile technologies, and its partner Guardian Patch LLC, announced today that they are currently ramping-up efforts for the release of their Guardian Sphere tracking device, which is primarily designed for pets, but may also be used for tracking children, adults, including the disabled, inventory, artwork, or virtually any object located within an area covered by the device.

The Guardian Sphere (the "Sphere") system is a derivative technology of the Company's Guardian Patch technology. The Sphere is designed to provide its users with local tracking capability using a re-chargeable/replaceable battery source. The Sphere is an innovative tracking device that can easily be attached to a pet's collar and then transmit real-time location information to the smartphone(s) or website account of the registered owner of the device. The Sphere has a replaceable battery and operates on the exclusive Guardian private network which provides owners with the unique ability to obtain real-time tracking information without the need for GPS, Wi-Fi or cellular service.

The Sphere includes state of the art radio technology, a GPS system and micro controller systems. It sends signals in specific intervals to report on its location. The system analyzes the information using its proprietary, advanced mathematical modeling software that precisely calculates the Sphere's location. The mobile application then presents the exact location of the Sphere on the map. An additional unique system feature is its own Emergency Alert system. The user has the ability to transmit an emergency alert on his or her Sphere's location, directly from the mobile app. All registered users located in that Sphere's proximity will be notified about the Emergency and may notify the user about the Sphere's recovery (which we fondly refer to as a "private emergency alert"). The Sphere utilizes is a bi-directional system which enables data transmission/receiving acknowledgment. It also includes error correction protocol to ensure data accuracy. The Sphere has its own battery source and may be plugged to external power using standard Android type charger socket. The Sphere comes with its own ID. This ID is registered on the mobile app to track the Sphere's location. Multiple Spheres can be registered on the same app for multiple tracking. It is an ideal tracking device for personal and commercial purposes for those seeking high-performance local tracking at an affordable price.

The Sphere represents the Company's entry into the burgeoning global pet wearable market, which is expected to reach USD 2.36 billion by 2022 according to a press release[1] issued by Grand View Research, Inc. in February 2016. According to Grand View's press release, "Growing pet ownership coupled with increasing per capita expenditure on pets is expected to drive product demand over the forecast period." In addition, as stated in a press release[2] issued by the Insurance Information Institute, according to the 2015-2016 National Pet Owners Survey conducted by the American Pet Products Association (APPA), Sixty-five percent of U.S. households, or about 79.7 million families, own a pet, which is up from 56 percent of U.S. households in 1988, the first year the survey was conducted. The Company believes that the above information suggests a significant potential market for the Sphere and one that the Company believes could potentially benefit from the Sphere.

"The current demand for GPS-based devices that are capable of providing real-time positioning of our loved ones and valuables is fueling global advancements in technologies which are enabling people to remain connected to the things that they value most. In millions of households across the world, pets are beloved members of the family. Our goal in developing the Sphere is to provide pet owners with peace of mind through the use an invaluable recovery tool which will enable them to track their pets in real-time should they ever become separated," stated Company CEO Michael Murray.

In addition to operating as a tracking device for household pets, the Company also recognizes an opportunity for the Sphere to be utilized for tracking valuable livestock on farms as well as animals registered as endangered species.

At the time of this press release, the Company has not specified a release date for the Sphere. The Company is committed to providing more definitive release date information in the coming weeks and is targeting a release date of approximately Q1 2017, of which there is no guarantee.

Read this release in full at http://www.investorideas.com/CO/GOPH/news/2016/09211GuardianSphere.asp

About Guardian Patch

The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application. Download the Patch app, register your patch, and track anything that you own on your mobile device or on our designated website. Register the Patches of your family members and friends to receive alerts in the event of an emergency. Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch.

About Gopher Protocol Inc.

Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher” and the "Company") (http://gopherprotocol.com/) is a development-stage company developing a real-time, heuristic-based mobile technology.  Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server.  The system contemplates the creation of a global network.  Gopher believes this will be among the first system that is developed using a human, heuristic-based analysis engine.  Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com

Press page/ press kit - http://gopherprotocol.com/?page_id=228

Consumer and product website for Guardian Patch: http://www.guardianpatch.com/

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

[1] https://www.grandviewresearch.com/press-release/global-pet-wearable-market

[2] http://www.iii.org/fact-statistic/pet-statistics

Contact:

Danny Rittman CTO
Gopher Protocol Inc.
VM Only - 888-685-7336

Media: press@gopherprotocol.com

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )

More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Actinium Pharmaceuticals (NYSE: $ATNM) to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical Trial

Actinium Pharmaceuticals (NYSE: $ATNM) to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical Trial

Webinar to be Held on Tuesday, September 27, 2016 at 9:00 AM ET

Webinar to feature Principle Investigator Joseph Jurcic, M.D., Professor of Clinical Medicine and Director of the Hematologic Malignancies Section of the Hematology/Oncology Division at Columbia University Medical Center

NEW YORK - September 21, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will host a webinar on Tuesday, September 27, 2016 at 9:00 AM ET to provide an update on the Actimab-A Phase 2 Clinical Trial. Details of the webinar are below:

Date: Tuesday, September 27, 2016 
Time: 9:00 AM ET 
Webinar Link:

https://onecast.thinkpragmatic.com/ses/awQiM-9OD7Iysoul6ZD6BQ~~

"Since presenting our Phase 1 data on June 1, 2016, we have made progress on our Actimab-A program", stated Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals. "We look forward to providing an update on the Actimab-A Phase 2 trial that will include the protocol changes that have been agreed to by the FDA."

Dr. Joseph Jurcic, M.D., Principle Investigator for the Actimab-A Phase 2 trial said, "Actimab-A is intended to treat patients over the age of 60 that are newly diagnosed with acute myeloid leukemia, which is a patient population with significant unmet medical needs. The results from the Actimab-A Phase 1 clinical trial showed an encouraging safety and efficacy profile that gives us great excitement for the Phase 2 clinical trial of Actimab-A."

The Actimab-A Phase 2 clinical trial is expected to begin in 2016 and will enroll 53 patients bringing the total number of patients in this Phase 1/2 Actimab-A trial to 71. This multi-center, open-label, single-arm Phase 2 trial will enroll patients newly diagnosed with AML who are over the age of 60. The Company will also be incorporating into the Phase 2 trial protocol changes including the removal of low dose cytarabine, the mandated use of granulocyte colony-stimulating factors (GCSF) and the mandated use of Hydroxyurea based on the findings from its peripheral blast (PB) burden hypothesis which was derived from the two Phase 1 clinical trials conducted with Actimab-A in its Hum195-Alpha clinical program.

Based on evidence that suggests that peripheral blasts prevent Actimab-A from reaching the bone marrow at optimal doses, the Company has mandated the use of Hydroxyurea to reduce the PB burden in patients above a certain key threshold. PB burden will serve as an inclusion criteria for the Phase 2 trial but it is not expected to exclude patients due to the ability of Hydroxyurea to reduce peripheral blasts. The end point of the Phase 2 trial will be complete response rate at up to 42 days after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017.

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09211ClinicalTrial.asp

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Actinium Pharmaceuticals (NYSE: $ATNM) Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 Trial

Actinium Pharmaceuticals (NYSE: $ATNM) Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 Trial

NEW YORK - September 20, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has selected Vector Oncology as its Clinical Research Organization (CRO) for its anticipated Actimab-A Phase 2 clinical trial.

"We are delighted to be working with Vector Oncology for our upcoming Phase 2 clinical trial," stated Dragan Cicic, M.D., Actinium’s Chief Medical Officer. "Vector Oncology displayed an expertise in hematology clinical trials with an emphasis on Phase 2 studies, which gives us great confidence in our selection. We look forward to working with Vector Oncology and to benefiting from their robust clinical capabilities."

Sean L. Hart, Executive Vice President and Managing Director at Vector Oncology said, "Vector Oncology is excited to be working with Actinium as a member of this important team. Since our first interaction with Actinium, all team members involved have committed to getting this important product in the hands of oncology professionals as soon as possible to advance the research efforts. We very much look forward to an exciting future together."

The Company recently completed a Phase 1 trial with Actimab-A in 18 patients newly diagnosed with Acute Myeloid Leukemia (AML) who are above the age of 60. The Phase 1 trial was a dose escalation study with fractionated dosing levels of Actimab-A ranging from 0.5 µCi/kg/fractionated dose to 2.0 µCi/kg/fractionated dose. Actinium announced that the dose for the Phase 2 clinical trial will be two doses of Actimab-A at 2.0 µCi/kg/fractionated dose one week apart, the highest dose level from the Phase 1 trial.

The Actimab-A Phase 2 clinical trial is expected to begin in 2016 and will enroll 53 patients bringing the total number of patients in this Phase 1/2 Actimab-A trial to 71. This multi-center, open-label, single-arm Phase 2 trial will enroll patients newly diagnosed with AML who are over the age of 60.The Company will also be incorporating into the Phase 2 trial protocol changes including the removal of low dose cytarabine, the mandated use of granulocyte colony-stimulating factors (GCSF) and the mandated use of Hydroxyurea based on the findings from its peripheral blast (PB) burden hypothesis which was derived from the two Phase 1 clinical trials conducted with Actimab-A in its Hum195-Alpha clinical program.

Based on evidence that suggests that peripheral blasts prevent Actimab-A from reaching the bone marrow at optimal doses, the Company has mandated the use of Hydroxyurea to reduce the PB burden in patients above a certain key threshold. PB burden will serve as an inclusion criteria for the Phase 2 trial but it is not expected to exclude patients due to the ability of Hydroxyurea to reduce peripheral blasts. The end point of the Phase 2 trial will be complete response rate at up to 42 days after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017.

Sandesh Seth, Actinium’s Executive Chairman said, "The selection of Vector Oncology as our CRO marks an important step in the development of Actimab-A. The Phase 2 Actimab-A trial is the second Phase 2 trial from our HuM195-Alpha program, albeit with a second generation, much superior product candidate and tantalizing results from the Phase 1 portion that should bode well for the progress of this trial. With the revised protocol, PB burden hypothesis and strengthened clinical development team we look forward to the Phase 2 trial of Actimab-A and working with Vector Oncology to ensure efficient and timely trial execution."

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09201Actimab-A.asp

About Vector Oncology

Vector Oncology is a leader in the design and delivery of care based oncology research and data analytics. Utilizing our comprehensive Oncology Data Warehouse and proprietary Patient Care Monitor (PCM) patient engagement and outcomes platform, our experienced project teams, medical experts and health economics and outcomes scientists design and deliver high-quality projects generating real world evidence and insight. With some of the most experienced medical, scientific, operational, and executive teams in late stage research, Vector Oncology is uniquely positioned to meet the demand to demonstrate product value in terms of economic impact, clinical effectiveness and tolerability, and patient reported outcomes (PRO). For more information, please visit www.vectoroncology.com.

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Vector Oncology
Sean Hart
Executive Vice President and Managing Director
shart@vectoroncology.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.